BioGaia

Regulatory Filings • Nov 22, 2012

Press Release 22 November 2012

BioGaia has entered into an exclusive agreement for its probiotic drops with Nestlé in Mexico

BioGaia has signed an agreement with Nestlé Mexico, for the exclusive rights to sell BioGaia's probiotic drops in Mexico from 2013. The product will be sold under the BioGaia brand.

This is the second contract with Nestlé since BioGaia's sale to Nestlé of license rights to use BioGaia's patented Lactobacillus reuteri Protectis in infant formula, announced in February 2012, at which time the two companies entered into a number of development and option agreements. The first contract, signed in June, was with Nestlé's Gerber division in the United States and included the probiotic drops and oral rehydration solution. As the oil drops already are on the market in Mexico, this is a part of BioGaia's on-going change of distributor programme.

The BioGaia ProTectis baby drops contains BioGaia's patented and well-researched probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in more than 50 countries.

"We are pleased with the agreement with Nestlé Mexico. With Nestlé's sales force of more than 100 sales representatives visiting pediatricians and their marketing capacity we are confident that sales will grow faster in this very important market", says Peter Rothschild, Chief Executive Officer, BioGaia.

For additional information please contact Peter Rothschild, Chief Executive Officer, BioGaia: +46 8 555 293 00

Latest press releases from BioGaia

2012-10-23	BioGaia AB Interim report 1 January-30 September 2012
2012-10-15	BioGaia's signs probiotic safe and effective in premature infants
2012-10-12	BioGaia signs exclusive distribution agreement for its probiotic drops and tablets in Pakistan

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 22 November 2012, 11:00 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, healthenhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com